CLINICAL TRIALS PROFILE FOR LORCASERIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Lorcaserin Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00395135 ↗ | BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management | Completed | Arena Pharmaceuticals | Phase 3 | 2006-11-01 | The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of treatment (Week 104) |
| NCT00395135 ↗ | BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management | Completed | Eisai Inc. | Phase 3 | 2006-11-01 | The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of treatment (Week 104) |
| NCT00603291 ↗ | BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus | Completed | Arena Pharmaceuticals | Phase 3 | 2007-12-01 | The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU), or either agent in combination with other oral hypoglycemic agents. |
| NCT00603291 ↗ | BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus | Completed | Eisai Inc. | Phase 3 | 2007-12-01 | The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU), or either agent in combination with other oral hypoglycemic agents. |
| NCT00603902 ↗ | BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management | Completed | Arena Pharmaceuticals | Phase 3 | 2008-01-01 | The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients. |
| NCT00603902 ↗ | BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management | Completed | Eisai Inc. | Phase 3 | 2008-01-01 | The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients. |
| NCT00828438 ↗ | Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment | Completed | Arena Pharmaceuticals | Phase 1 | 2008-10-01 | The purpose of this study is to evaluate the PK properties of lorcaserin in subjects with end stage renal disease (ESRD) who require dialysis and will be studied under dialysis and non-dialysis conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Lorcaserin Hydrochloride
Condition Name
Clinical Trial Locations for Lorcaserin Hydrochloride
Trials by Country
Clinical Trial Progress for Lorcaserin Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Lorcaserin Hydrochloride
Sponsor Name
